The U.S. market size is calculated at USD 146.04 billion in 2025 and is forecasted to reach around USD 231.69 billion by 2034, accelerating at a CAGR of 5.24% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: US Generic Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US Generic Drugs Market Revenue and Volume, by Drug Type
8.1.1. Simple Generics
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Super Generics
8.1.2.1. Market Revenue and Volume Forecast
9.1. US Generic Drugs Market Revenue and Volume, by Brand
9.1.1. Pure Generic Drugs
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Branded Generic Drugs
9.1.2.1. Market Revenue and Volume Forecast
10.1. US Generic Drugs Market Revenue and Volume, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Injection
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Cutaneous
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. US Generic Drugs Market Revenue and Volume, by Therapeutic Application
11.1.1. Central Nervous System (CNS)
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Musculoskeletal Diseases
11.1.4.1. Market Revenue and Volume Forecast
11.1.5. Respiratory
11.1.5.1. Market Revenue and Volume Forecast
11.1.6. Oncology
11.1.6.1. Market Revenue and Volume Forecast
11.1.7. Others
11.1.7.1. Market Revenue and Volume Forecast
12.1. US Generic Drugs Market Revenue and Volume, by Distribution Channels
12.1.1. Retail Pharmacy
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Hospital Pharmacy
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Online and Others
12.1.3.1. Market Revenue and Volume Forecast
13.1. U.S.
13.1.1. Market Revenue and Volume Forecast, by Drug Type
13.1.2. Market Revenue and Volume Forecast, by Brand
13.1.3. Market Revenue and Volume Forecast, by Route of Administration
13.1.4. Market Revenue and Volume Forecast, by Therapeutic Application
13.1.5. Market Revenue and Volume Forecast, by Distribution Channels
14.1. Pfizer Inc
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Teva Pharmaceuticals USA, Inc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Aurobindo Pharma USA, Inc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Sun pharma Inc
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Abbott Laboratories Inc
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Lupin Pharmaceuticals, Inc
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Mylan
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Dr. Reddy’s
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Novartis
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eli Lilly company
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample